Car T Kymriah denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Non-Formulary Denial for Kymriah

Kymriah (tisagenlecleucel) is a specialty biologic and CAR-T cell therapy. UnitedHealthcare's formulary tiers are structured primarily around traditional oral and injectable drugs; CAR-T therapies often sit outside the standard formulary structure entirely, leading to automatic non-formulary denials even when the therapy is medically appropriate and FDA-approved. These denials are frequently administrative in origin rather than a clinical judgment about your patient.

## Why This Denial Is Appealable

A non-formulary denial is one of the most commonly overturned denial categories. When no formulary alternative exists that treats the same FDA-approved indication — which is typically the case for Kymriah, an individualized cell therapy — the plan generally cannot require substitution. Your appeal should establish that the non-formulary label is irrelevant to coverage because there is no therapeutically equivalent formulary alternative for this patient's specific condition.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your Explanation of Benefits. Clearly state that no formulary alternative exists for Kymriah's approved indication.
• Expedited review: Request if delay would seriously jeopardize health — CAR-T eligibility windows can be clinically time-sensitive.
• External Independent Review (ACA §2719): If the internal appeal is denied, escalate to IRO review. The insurer is bound by the IRO's determination.
• ERISA §503: Employer-plan members retain full-and-fair review rights; the external-review window is approximately four months from the original denial.

## Documentation to Gather

1. Diagnosis and FDA-indication match — confirm in writing that the patient's diagnosis and prior-treatment history align with the exact indication listed in Kymriah's FDA-approved prescribing label. 2. No formulary alternative — request from UHC a list of any formulary agents it considers therapeutically equivalent; document why each listed alternative is not appropriate (different mechanism, different indication, or previously tried and failed). 3. Prior-treatment records — dates, regimens, and outcomes for all prior lines of therapy. 4. Prescriber letter — a letter explaining the absence of a clinically equivalent formulary substitute and the medical necessity of Kymriah specifically. 5. Facility authorization — CAR-T-certified center documentation.

## Criteria-Mapping Structure

Pull UHC's published formulary exception policy and its coverage policy for tisagenlecleucel. Create a two-column table: left column lists each non-formulary exception criterion; right column cites the specific chart fact, test result, or clinical note that satisfies it. For any criterion that references a therapeutic alternative, document in the table each alternative considered and the clinical reason it was excluded. A precise criterion-by-criterion map eliminates ambiguity and makes denial on remand much harder to sustain.